Eur Rev Med Pharmacol Sci 2019; 23 (20): 8806-8812

DOI: 10.26355/eurrev_201910_19275

MiR-652-3p promotes bladder cancer migration and invasion by targeting KCNN3

Q.-L. Zhu, D.-M. Zhan, Y.-K. Chong, L. Ding, Y.-G. Yang

Department of Urology Surgery, Jiangdu People’s Hospital of Yangzhou, Yangzhou, P.R. China. qingliang_zhu@126.com


OBJECTIVE: Increasing evidence indicated that microRNAs (miRNAs) are crucial regulators for cancer development. Bladder cancer (BCa) is a major threat to human health. The aim of this study was to analyze the roles of miR-652-3p in BCa, and to explore the associated mechanisms.

MATERIALS AND METHODS: MiR-652-3p expression in BCa cell lines was explored using Real Time-quantitative Polymerase Chain Reaction (RT-qPCR) method. MiR-652-3p expression level in BCa tissues was explored at StarBase. Cell Counting Kit-8 (CCK-8) assay, wound-healing assay, and transwell invasion assay were conducted to investigate the biological roles of miR-652-3p. The underlying mechanisms of miR-652-3p in NSCLC were investigated using luciferase activity reporter assay and rescue experiments.

RESULTS: We showed that miR-652-3p expression level was upregulated in both BCa tissues and cell lines. The knockdown of miR-652-3p significantly inhibited BCa cell proliferation, migration, and invasion in vitro. Moreover, we showed that potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 (KCNN3) was a functional target for miR-652-3p. Besides, the expression of KCNN3 in BCa tissues was negatively correlated with miR-652-3p.

CONCLUSIONS: Collectively, these results showed that miR-652-3p could promote BCa cell proliferation, migration, and invasion via directly regulating KCNN3, which may provide a novel therapeutic target for BCa treatment.

Free PDF Download

To cite this article

Q.-L. Zhu, D.-M. Zhan, Y.-K. Chong, L. Ding, Y.-G. Yang
MiR-652-3p promotes bladder cancer migration and invasion by targeting KCNN3

Eur Rev Med Pharmacol Sci
Year: 2019
Vol. 23 - N. 20
Pages: 8806-8812
DOI: 10.26355/eurrev_201910_19275